Clinical Trial Update: Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II [NA]

View source ↗

Summary

Clinical trial DACG-II is an active, not recruiting study exploring bone-sparing chemoradiotherapy for anal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer

Snippet

Sponsor: Karen-Lise Garm Spindler | Conditions: Anal Cancer, Radiotherapy Side Effect | NA | Status: ACTIVE_NOT_RECRUITING